C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 21, 2024, covers the results of the Annual Meeting of Stockholders held on June 20, 2024. C4 Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Watertown, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol CCCC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Class I Directors: Stockholders elected Kenneth Anderson, M.D., Laura Bessen, M.D., and Owen Hughes to serve until the 2027 annual meeting.
- Kenneth Anderson, M.D.: 38,005,401 votes For; 8,553,384 votes Withheld.
- Laura Bessen, M.D.: 37,738,853 votes For; 8,819,932 votes Withheld.
- Owen Hughes: 27,472,145 votes For; 19,086,640 votes Withheld.
- Advisory Vote on Executive Compensation: Stockholders cast a non-binding vote to approve the compensation of named executive officers.
- 34,500,552 votes For; 11,936,841 votes Against; 121,392 votes Abstain.
- Ratification of Independent Auditor: Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- 54,362,556 votes For; 170,867 votes Against; 34,074 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (Kenneth Anderson, Laura Bessen, and Owen Hughes) through the 2027 annual meeting.
- Note the significant number of votes withheld for Owen Hughes (19,086,640) compared to the other director nominees.
- Confirm the approval of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024.
- Review the advisory vote on executive compensation, which received approximately 74% support (For votes divided by total votes cast excluding broker non-votes).